MRK Merck & Co., Inc. |
$83.96
+6.8% |
-0.2%
 |
sotatercept-csrk
In adults with pulmonary arterial hypertension
|
Phase 3
|
9/30/2025 - Positive Results
Merck announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept…
Full Summary
|
UPB Upstream Bio |
$18.81
+8.5% |
+9.8%
 |
Verekitug
In Chronic Obstructive Pulmonary Disease (COPD)
|
|
9/30/2025 - Data
Upstream Bio, Inc today presented structural and mechanistic data showing verekitug's potent pharmac…
Full Summary
|
LIFE aTyr Pharma |
|
|
Efzofitimod
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
|
Phase 3
|
9/30/2025 - Findings Update
aTyr Pharma, Inc. today presented additional findings from the Phase 3 EFZO-FIT™ study of efzofitimo…
Full Summary
|
OCUL Ocular Therapeutix |
$11.69
-6.7% |
-4.3%
 |
AXPAXLI
In Diabetic Retinopathy
|
|
9/30/2025 - Provided Update
Ocular Therapeutix, Inc. announce plans for a registrational program in non-proliferative diabetic r…
Full Summary
|
OCUP Ocuphire Pharma |
|
|
OPGx-LCA5
For LCA5
|
Phase 1/2
|
9/30/2025 - Positive Data
Opus Genetics, Inc. announced positive three-month data from the pediatric cohort of its ongoing Pha…
Full Summary
|
DTIL Precision BioSciences |
$5.52
+8.4% |
+12.7%
 |
ARCUS
Eliminate DNA of living cells and organisms.
|
|
9/30/2025 - Late Breaking Presentation
Precision BioSciences, Inc. announced a late-breaking poster presentation at the 30th Annual Inter…
Full Summary
|
DTIL Precision BioSciences |
$5.52
+8.4% |
+12.7%
|
ARCUS
Eliminate DNA of living cells and organisms.
|
|
9/30/2025 - Provided Update
Precision BioSciences, Inc announced that its On track to file an IND and/or CTA by the end of 20…
Full Summary
|
NUVB Nuvation Bio |
$3.70
+14.9% |
+24.4%
 |
IBTROZI
In Advanced ROS1-Positive Non-Small Cell Lung Cancer
|
Phase 3
|
9/30/2025 - Enrollment Update
Nuvation Bio Inc announced it has enrolled the first patient in TRUST-IV (NCT07154706), a Phase 3 st…
Full Summary
|
SCYX SCYNEXIS |
$0.77
-26.7% |
-7.4%
 |
SCY-247
For systemic fungal diseases
|
Phase 1
|
9/30/2025 - Positive Results
SCYNEXIS, Inc. announced positive results from a Phase 1 study of SCY-247, its second-generation tr…
Full Summary
|
ECOR electroCore |
$4.95
+1.0% |
-6.8%
 |
gammaCore nVNS
Acute and preventive treatment of migraine in adolescents between 12 and 17 years of age
|
|
9/30/2025 - Publication
electroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demon…
Full Summary
|
NTRA Natera |
$160.97
-1.3% |
-4.3%
 |
Signatera
MRD Test for cancer therapies
|
|
9/30/2025 - Publication
Natera, Inc announcedthe publication of a peer-reviewed manuscript in the Journal of Clinical Oncol…
Full Summary
|
ABBV AbbVie |
$231.47
+3.7% |
+10.1%
 |
CADENZA
Treat Rare Cancer with Limited Treatment Options
|
BLA
|
9/30/2025 - BLA Filing
AbbVie announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug A…
Full Summary
|
LPCN Lipocine |
$2.85
+1.4% |
-2.1%
 |
LPCN 1154
Postpartum depression (PPD)
|
Phase 3
|
9/30/2025 - Provided Update
Lipocine Inc today provided an update on its ongoing pivotal Phase 3 clinical trial evaluating LPCN …
Full Summary
|
LPCN Lipocine |
$2.85
+1.4% |
-2.1%
|
LPCN 1154
Postpartum depression (PPD)
|
Target date: Q2 2026
|
9/30/2025 - Top-line results
Lipocine Inc announced that The study is progressing on track with one-third of planned patients ra…
Full Summary
|
CLRB Cellectar Biosciences |
$5.60
+3.5% |
+15.0%
 |
Iopofosine I-131
Pediatric Brain and Solid Tumors
|
|
9/30/2025 - Provided Update
Cellectar Biosciences, announced that Jarrod Longcor, chief operating officer of Cellectar, delivere…
Full Summary
|
SLS SELLAS Life Sciences Group |
$1.61
+3.2% |
-16.1%
 |
SLS009
For Treatment of Acute Myeloid Leukemia
|
|
9/30/2025 - Provided Update
SELLAS Life Sciences Group, announced that it will host a virtual R&D Day on Wednesday, October 29, …
Full Summary
|
PYPD PolyPid |
$3.34
+0.3% |
-0.3%
 |
D-PLEX100
Surgical Site Infections in Colorectal Surgery
|
|
9/30/2025 - Results
PolyPid Ltd. announced that Dr. Shmuel Sharoni will present the topline results from the Company's s…
Full Summary
|
SVRA Savara |
$3.57
+1.4% |
+8.8%
 |
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
Phase 3
|
9/29/2025 - Analysis
Savara Inc. announced additional analyses from its pivotal Phase 3 IMPALA-2 clinical trial of molgr…
Full Summary
|
PRTC PureTech Health |
$18.37
+1.8% |
+7.6%
 |
LYT-100-COV (deupirfenidone)
Post-acute Long COVID with respiratory complications
|
Phase 2b
|
9/29/2025 - New Data
PureTech Health plc announced new data from the open-label extension (OLE) of its Phase 2b ELEVAT…
Full Summary
|
AZN AstraZeneca |
$76.72
+3.5% |
-4.0%
 |
Enhertu (Trastuzumab deruxtecan)
Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
|
9/29/2025 - Positive Results
AstraZeneca announced Positive high-level results from a planned interim analysis of the DESTINY-Bre…
Full Summary
|
RAPT Rapt Therapeutics |
$25.79
-3.1% |
+126.6%
 |
RPT904
Food Allergy
|
NDA
|
9/29/2025 - FDA Clearance
RAPT Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared RAPT…
Full Summary
|
ENTA Enanta Pharmaceuticals |
$11.97
-21.0% |
+42.5%
 |
zelicapavir
For respiratory syncytial virus
|
Phase 2b
|
9/29/2025 - Top-line data
Enanta Pharmaceuticals, Inc announced positive topline data from RSVHR, a Phase 2b, randomized, doub…
Full Summary
|
LRMR Larimar Therapeutics |
$3.23
-4.4% |
-10.8%
 |
nomlabofusp
For Friedreich's Ataxia
|
|
9/29/2025 - Positive Data
Larimar Therapeutics, announced positive 25 mg and 50 mg data from the ongoing long-term open label …
Full Summary
|
TNXP Tonix Pharmaceuticals |
$24.16
-2.4% |
-18.5%
 |
TNX-2900
Prader-Willi Syndrome
|
|
9/29/2025 - Provided Update
Tonix Pharmaceuticals announced plans to progress its TNX-2900 program for the treatment of Prader-…
Full Summary
|
VOR Vor Biopharma |
$48.72
+22.1% |
+23.7%
 |
telitacicept
Sjögren's Disease
|
Phase 3
|
9/29/2025 - Clinical Data
Vor Bio announced that clinical data from the Phase 3 study in China evaluating telitacicept in adul…
Full Summary
|
APLT Applied Therapeutics |
$0.60
-1.1% |
+22.8%
 |
govorestat
For the Treatment of Classic Galactosemia
|
Target date: Q3 2025
|
9/29/2025 - FDA Meeting
Applied Therapeutics, Inc. announced that the Company completed a meeting with the U.S. Food and Dr…
Full Summary
|
CLYM Climb Bio |
$2.01
+1.0% |
-9.9%
 |
CLYM116
for IgAN
|
|
9/29/2025 - Results
Climb Bio, Inc. announced results from a completed nonhuman primate (NHP) study comparing CLYM116 t…
Full Summary
|
CTSO Cytosorbents |
$0.93
+0.9% |
-1.0%
 |
DrugSorb-ATR
Antithrombotic Removal System
|
|
9/29/2025 - Provided Update
CytoSorbents Corporation announced its strong scientific presence at the upcoming European Associati…
Full Summary
|
RGNX REGENXBIO |
$9.65
-2.0% |
+8.1%
 |
RGX-202
Duchenne Muscular Dystrophy
|
|
9/29/2025 - Presentation
REGENXBIO Inc announced Chief Medical Officer, Steve Pakola, M.D., will present at the International…
Full Summary
|
MDCX Medicus Pharma |
$2.32
-7.6% |
+19.6%
 |
SKNJCT-004
To Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
|
FDA Type C Meeting
|
9/29/2025 - Positive Feedback
Medicus Pharma Ltd is pleased to announce positive feedback from Type C meeting with United States…
Full Summary
|
CYTK Cytokinetics |
$54.96
+2.0% |
+55.6%
 |
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
|
|
9/29/2025 - Presentation
Cytokinetics, Incorporated announced that additional data related to aficamten were presented in a L…
Full Summary
|
ECOR electroCore |
$4.95
+1.0% |
-6.8%
|
gammaCore nVNS
Acute and preventive treatment of migraine in adolescents between 12 and 17 years of age
|
|
9/29/2025 - Provided Update
electroCore, Inc. announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbu…
Full Summary
|
KALA KALA BIO |
$1.53
-25.4% |
-86.4%
 |
KPI-012
Clinical diagnosis of PCED
|
Phase 2b
|
9/29/2025 - Endpoint Missed
KALA BIO, Inc. announced that its CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical …
Full Summary
|
INMB INmune Bio |
$2.07
-1.9% |
+2.0%
 |
XPro1595
Alzheimer’s disease
|
Phase 2
|
9/29/2025 - Provided Update
INmune Bio, Inc. announces the submission of a manuscript detailing the results of its Phase 2 MINDF…
Full Summary
|
JNJ Johnson & Johnson |
$185.40
+2.1% |
+4.7%
 |
Guselkumab
For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
|
|
9/29/2025 - FDA approved
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (…
Full Summary
|
CADL Candel Therapeutics |
$5.10
-5.6% |
-11.9%
 |
CAN-2409
Prostate cancer
|
Phase 3
|
9/29/2025 - Analysis
Candel Therapeutics, Inc presented subgroup analyses focused on the radiation regimen from the Comp…
Full Summary
|
NRXP NRx Pharmaceuticals |
$3.30
+1.5% |
+42.2%
 |
KETAFREE™
preservative-free ketamine product
|
ANDA
|
9/29/2025 - re-filing
NRx Pharmaceuticals, announced the re-filing of its Abbreviated New Drug Application (ANDA) to the U…
Full Summary
|
OTLK Oncobiologics |
$1.06
|
+24.5%
 |
ONS-5010 / LYTENAVA (Bevacizumab-vikg)
Wet age-related macular degeneration (wet AMD)
|
FDA Type C Meeting
|
9/29/2025 - FDA Meeting
- Outlook Therapeutics, Inc y announced that it has completed the Type A Meeting with the U.S. Food…
Full Summary
|
CADL Candel Therapeutics |
$5.10
-5.6% |
-11.9%
|
CAN-2409
Prostate cancer
|
|
9/29/2025 - Presentation
Candel Therapeutics, Inc. presented subgroup analyses focused on the radiation regimen from the Comp…
Full Summary
|
GH Guardant Health |
$62.48
+0.8% |
-7.3%
 |
Guardant360
Advanced solid tumors.
|
|
9/29/2025 - FDA approved
Guardant Health, Inc announced that the U.S. Food and Drug Administration (FDA) has approved its Gu…
Full Summary
|
NVCR NovoCure |
$12.92
|
+4.8%
 |
Tumor Treating Fields - METIS
Brain metastases
|
Phase 3
|
9/29/2025 - Results
Novocure nnounced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields…
Full Summary
|
NBTX Nanobiotix |
$18.89
+4.8% |
+111.3%
 |
JNJ-1900
for patients with cancer
|
|
9/29/2025 - Updated data
NANOBIOTIX announced updated data from cohorts 1 and 2 of Study 1100, a multicenter Phase 1 dose esc…
Full Summary
|
EPRX Eupraxia Pharmaceuticals |
$5.90
+2.6% |
+10.1%
 |
EP-104GI
For Treatment of Eosinophilic Esophagitis
|
|
9/29/2025 - Provided Update
Eupraxia Pharmaceuticals Inc today provided an operational update on the development of EP-104GI, …
Full Summary
|
MSTR Strategy |
$322.57
-1.2% |
-3.5%
 |
MET-097i
GLP-1 RA Candidate
|
Phase 2b
|
9/29/2025 - Top-line data
Metsera, Inc announced positive topline data from VESPER-1 and positive data from a planned interim…
Full Summary
|
KURA Kura Oncology |
$8.85
-1.3% |
+12.0%
 |
Ziftomenib
Treatment of genetically defined AML patients with high unmet need
|
|
9/29/2025 - Dose Update
Kura Oncology, announced that the first patient has been dosed under the KOMET-017 clinical trial pr…
Full Summary
|
LQDA Liquidia Technologies |
$22.74
-0.3% |
-17.8%
 |
LIQ861 (Treprostinil)
Pulmonary arterial hypertension (PAH)
|
|
9/29/2025 - Oral presentation
Liquidia Corporation announced today the company will present two oral presentations at the CHEST 2…
Full Summary
|
CNTB Connect Biopharma |
$1.51
+14.6% |
-26.7%
 |
IL-4Rα
For asthma
|
|
9/29/2025 - Data Presentation
Connect Biopharma Holdings today presented data supporting rademikibart, the Company's investigatio…
Full Summary
|
CRMD CorMedix |
$11.63
-1.9% |
-21.6%
 |
REZZAYO
in the prevention of Candida, Aspergillus, and Pneumocystis infection in patients undergoing allogeneic blood and marrow transplantation (BMT).
|
Target date: Q2 2026
|
9/29/2025 - Top-line results
CorMedix Inc. announced that Topline Results from ReSPECT Study Expected in 2Q 2026
Full Summary
|
CRMD CorMedix |
$11.63
-1.9% |
-21.6%
|
REZZAYO
in the prevention of Candida, Aspergillus, and Pneumocystis infection in patients undergoing allogeneic blood and marrow transplantation (BMT).
|
Phase 3
|
9/29/2025 - Enrollment Completion
CorMedix Inc.announced completion of enrollment for the ongoing, global Phase III ReSPECT trial eval…
Full Summary
|
ALNY Alnylam Pharmaceuticals |
$456.00
+1.9% |
+2.1%
 |
Vutrisiran (HELIOS-B)
Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
|
Phase 3
|
9/28/2025 - Results
Alnylam Pharmaceuticals today announced results from new analyses of the HELIOS-B Phase 3 study of …
Full Summary
|
BIIB Biogen |
$140.08
+1.1% |
+5.9%
 |
LEQEMBI® (lecanemab-irmb)
Treatment of Alzheimer's Disease
|
|
9/28/2025 - Provided Update
Eisai Co., and Biogen Inc. announced that humanized anti-soluble aggregated amyloid-beta (Aβ) monoc…
Full Summary
|
LRMR Larimar Therapeutics |
$3.23
-4.4% |
-10.8%
|
nomlabofusp
For Friedreich's Ataxia
|
|
9/28/2025 - Provided Update
Larimar Therapeutics, announced that the Company will host a conference call and webcast to discuss …
Full Summary
|
INCY Incyte |
$84.81
+1.1% |
+0.2%
 |
ruxolitinib cream
Atopic dermatitis (AD), a type of eczema
|
Phase 3
|
9/28/2025 - Positive Results
China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon…
Full Summary
|
MESO Mesoblast |
$16.11
+0.6% |
+16.5%
 |
RYONCIL
For the treatment of severe and life-threatening inflammatory conditions.
|
|
9/26/2025 - Provided Update
Mesoblast Limited today reiterated that its allogeneic cell therapy products are manufactured from …
Full Summary
|
KALV KalVista Pharmaceuticals |
$12.18
-0.2% |
-9.5%
 |
sebetralstat
Therapy for hereditary angioedema (HAE).
|
|
9/26/2025 - Presentation
KalVista Pharmaceuticals, Inc announced the acceptance of six abstracts for ePoster presentation at…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$562.27
+0.3% |
-3.2%
 |
Evkeeza
treatment of children from age 1 to less than 5 years old with homozygous familial hypercholesterolemia (HoFH).
|
|
9/26/2025 - FDA Meeting Request
Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved E…
Full Summary
|
ABBV AbbVie |
$231.47
+3.7% |
+10.1%
|
Tavapadon
Parkinson’s disease
|
NDA
|
9/26/2025 - NDA Filing
AbbVie announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Admini…
Full Summary
|
TLSA Tiziana Life Sciences |
$2.16
+1.4% |
+19.3%
 |
ECTRIMS
Pathogenesis of neuroinflammatory diseases
|
|
9/25/2025 - Presentation
Immunic, Inc announced the presentation of key data in an oral and four poster presentations, includ…
Full Summary
|
MRK Merck & Co., Inc. |
$83.96
+6.8% |
-0.2%
|
EV-303
For Certain Patients with Muscle-Invasive Bladder Cancer
|
|
9/25/2025 - Highlights
Pfizer Inc will highlight data across its extensive Oncology portfolio at the European Society for M…
Full Summary
|
BMY Bristol Myers Squibb |
$45.00
+1.9% |
-4.6%
 |
Deucravacitinib
Moderate to severe plaque psoriasis
|
|
9/25/2025 - Expansion
Bristol Myers Squibb announced an expansion of its direct-to-patient offerings, providing eligible …
Full Summary
|
ACIU AC Immune |
$2.89
-4.9% |
+41.7%
 |
ACI-35.030
Alzheimer’s Disease (AD)
|
|
9/25/2025 - Publication
AC Immune SA announced the peer-reviewed publication in eBioMedicine of results from the completed P…
Full Summary
|
LPTX Leap Therapeutics |
$0.45
+26.2% |
+57.4%
 |
DKN-01
Advanced gynecological malignancies
|
|
9/25/2025 - Results
Leap Therapeutics, Inc announced it will present the final clinical results from Part B of the DeF…
Full Summary
|
CAPR Capricor Therapeutics |
$7.21
-2.7% |
+14.8%
 |
deramiocel
For the treatment of Duchenne muscular dystrophy (DMD)
|
BLA
|
9/25/2025 - Provided Update
Capricor Therapeutics announced a regulatory update for its Biologics License Application (BLA) for …
Full Summary
|
MDWD MediWound |
$18.02
+0.3% |
+7.9%
 |
NexoBrid
Enzymatically removes nonviable burn tissue
|
Australian TGA Approval
|
9/25/2025 - Marketing authorization
MediWound Ltd. announced that Australia's Therapeutic Goods Administration (TGA) has granted marketi…
Full Summary
|
VCEL Vericel |
$31.47
-1.0% |
-13.4%
 |
NexoBrid
Enzymatically removes nonviable burn tissue
|
Australian TGA Approval
|
9/25/2025 - Marketing authorization
MediWound Ltd. announced that Australia's Therapeutic Goods Administration (TGA) has granted marketi…
Full Summary
|
ANEB Anebulo Pharmaceuticals |
$2.50
+3.3% |
|
Selonabant
for Acute Cannabis-Induced Toxicity
|
Phase 1
|
9/25/2025 - Dose Update
Anebulo Pharmaceuticals, Inc announces the first subjects dosed in its Phase 1 single ascending dos…
Full Summary
|
VRTX Vertex Pharmaceuticals |
$391.64
-0.9% |
+0.2%
 |
inaxaplin
APOL1-mediated kidney disease
|
|
9/25/2025 - Provided Update
Vertex Pharmaceuticals Incorporated announced several important advancements across its programs i…
Full Summary
|
VNDA Vanda Pharmaceuticals |
$4.99
+1.6% |
+5.5%
 |
HETLIOZ
For treat jet lag disorder
|
|
9/25/2025 - Publication
Vanda Pharmaceuticals Inc. announced the publication of an article titled "Melatonin agonist tasime…
Full Summary
|
TLSA Tiziana Life Sciences |
$2.16
+1.4% |
+19.3%
|
TZLS-501
A Fully Human anti-IL-6 receptor Monoclonal Antibody
|
|
9/25/2025 - Provided Update
Tiziana Life Sciences, Ltd announces it will advance its second asset, a fully human anti-IL-6 recep…
Full Summary
|
NTLA Intellia Therapeutics |
$17.27
+2.1% |
+52.2%
 |
nex-z
For Transthyretin (ATTR) Amyloidosis with Polyneuropathy
|
|
9/25/2025 - Data
Intellia Therapeutics, announced longer-term follow-up data from the ongoing Phase 1 study of invest…
Full Summary
|
LLY Eli Lilly and Company |
$763.01
+5.0% |
+4.2%
 |
Imlunestrant
oral selective estrogen receptor degrader
|
|
9/25/2025 - FDA approved
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved …
Full Summary
|
SNY Sanofi |
$47.20
+3.4% |
-4.6%
 |
vandetanib
thyroid cancer treatment
|
|
9/25/2025 - Provided Update
Sanofi SA announced that The U.S. Food and Drug Administration today removed the Risk Evaluation an…
Full Summary
|
CDTX Cidara Therapeutics |
$95.76
+0.5% |
+46.4%
 |
CD388
Universal Prevention and Treatment of Influenza
|
Phase 3
|
9/25/2025 - Dosing Update
Cidara Therapeutics, Inc announced that the first participants have been dosed in its Phase 3 trial …
Full Summary
|
KURA Kura Oncology |
$8.85
-1.3% |
+12.0%
|
Ziftomenib
Treatment of genetically defined AML patients with high unmet need
|
|
9/25/2025 - Publication
Kura Oncology, announced the Journal of Clinical Oncology published the full results from the pivota…
Full Summary
|
ORGO Organogenesis |
$4.22
-0.9% |
-18.1%
 |
ReNu
for Knee Osteoarthritis
|
Phase 3
|
9/25/2025 - Endpoint Missed
Organogenesis Holdings announced that the second Phase 3 randomized controlled trial (RCT) of ReNu, …
Full Summary
|
ZBH Zimmer Biomet |
$98.49
+0.2% |
-7.2%
 |
iTaperloc
First Iodine-Treated Total Hip Replacement System
|
Japanese Pharmaceuticals and Medical Devices Agency (PMDA) Approval
|
9/25/2025 - Approved
Zimmer Biomet Holdings announced the Pharmaceutical and Medical Devices Agency (PMDA) in Japan appr…
Full Summary
|
QNCX Quince Therapeutics |
$1.63
+1.2% |
+1.9%
 |
eDSP
For Treatment Of Rare Neurodegenerative Disease Ataxia-Telangiectasia
|
Phase 3
|
9/25/2025 - Publication
Quince Therapeutics, Inc. announced the publication of an advanced population pharmacokinetic (PK)…
Full Summary
|
CRNX Crinetics Pharmaceuticals |
$41.65
-4.3% |
+34.4%
 |
Paltusotine
Acromegaly
|
|
9/25/2025 - FDA approved
Crinetics Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) approved PALSO…
Full Summary
|
LLY Eli Lilly and Company |
$763.01
+5.0% |
+4.2%
|
Donanemab
Alzheimer's disease (AD)
|
European Commission
|
9/25/2025 - Marketing authorization
Eli Lilly and Company announced today that the European Commission (EC) has granted marketing autho…
Full Summary
|
AZN AstraZeneca |
$76.72
+3.5% |
-4.0%
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki)
For the treatment of adult patients with unresectable or metastatic HER2 positive
|
sBLA Priority Review
|
9/24/2025 - FDA Accepted
AstraZeneca and Daiichi Sankyo announced that supplemental Biologics License Application (sBLA) fo…
Full Summary
|
BNR Burning Rock Biotech |
$8.65
-7.9% |
+1.1%
 |
Capivasertib
in Breast Cancer
|
MHLW Approval
|
9/24/2025 - Approved
Riken Genesis Co., Ltd. and Burning Rock Biotech Limited announced that the OncoGuide™ OncoScreen™ P…
Full Summary
|
CDTX Cidara Therapeutics |
$95.76
+0.5% |
+46.4%
|
CD388
Universal Prevention and Treatment of Influenza
|
Phase 3
|
9/24/2025 - Provided Update
Cidara Therapeutics, Inc. announced updates to its planned Phase 3 registrational trial of CD388 fo…
Full Summary
|
FGEN FibroGen |
$12.25
-0.5% |
+3.6%
 |
FG-3246
In Patients with Metastatic Castration-Resistant Prostate Cancer
|
Phase 2
|
9/24/2025 - Initiation
FibroGen, announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a…
Full Summary
|
ACAD ACADIA Pharmaceuticals |
$21.34
+0.1% |
-17.9%
 |
ACP-101
For the treatment of hyperphagia in Prader-Willi syndrome (PWS).
|
Phase 3
|
9/24/2025 - Top-line results
Acadia Pharmaceuticals Inc. announced top-line results from the Phase 3 COMPASS PWS trial evaluati…
Full Summary
|
SMMT Summit Therapeutics |
$20.66
-2.4% |
-12.8%
 |
Ivonescimab
For Lung cancer
|
Phase 3
|
9/24/2025 - Data
Summit Therapeutics Inc announced that data from the Phase III HARMONi-6 trial, conducted in China…
Full Summary
|
BIIB Biogen |
$140.08
+1.1% |
+5.9%
|
Lecanemab (BAN2401)
Anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD)
|
Australian TGA Approval
|
9/24/2025 - Approved
Eisai Co. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has…
Full Summary
|
COCH Envoy Medical |
$0.78
-3.0% |
-36.9%
 |
Acclaim
for Breakthrough Hearing Device
|
|
9/24/2025 - Provided Update
Envoy Medical® Inc announced it is scaling its commercialization planning for the company's breakthr…
Full Summary
|
NRXP NRx Pharmaceuticals |
$3.30
+1.5% |
+42.2%
|
KETAFREE™
preservative-free ketamine product
|
|
9/24/2025 - Provided Update
NRx Pharmaceuticals, announced that it was notified yesterday by the United States Food and Drug Ad…
Full Summary
|
HRMY Harmony Biosciences |
$27.56
-0.3% |
-25.3%
 |
ZYN002
In Fragile X Syndrome
|
Phase 3
|
9/24/2025 - Top-line results
Harmony Biosciences Holdings, Inc announced topline results from its Phase 3 registrational clinica…
Full Summary
|
CLRB Cellectar Biosciences |
$5.60
+3.5% |
+15.0%
|
CLR 125
For the treatment of relapsed TNBC.
|
Phase 1b
|
9/24/2025 - Provided Update
Cellectar Biosciences, Inc. have entered into an agreement whereby Evestia will provide Cellectar w…
Full Summary
|
AKTX Akari Therapeutics |
$1.01
-1.1% |
+32.9%
 |
AR-V7
for the treatment of tumors fueled by alternative splicing-drivers, such as the Androgen Receptor splice variant 7 (AR-V7) in prostate cancer.
|
|
9/24/2025 - Preclinical Data
Akari Therapeutics announced key preclinical data demonstrating the potential of its novel antibody…
Full Summary
|
SNY Sanofi |
$47.20
+3.4% |
-4.6%
|
SAR446268
for the treatment of non-congenital myotonic dystrophy type 1
|
Fast Track
|
9/23/2025 - Designation Grant
Sanofi announced that The US Food and Drug Administration (FDA) has granted fast track designation …
Full Summary
|
ABBV AbbVie |
$231.47
+3.7% |
+10.1%
|
SKINVIVE
Advancing Global Skin Quality
|
|
9/23/2025 - Roll Out
Allergan Aesthetics, an AbbVie company announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additi…
Full Summary
|
BMY Bristol Myers Squibb |
$45.00
+1.9% |
-4.6%
|
iberdomide
Relapsed or Refractory Multiple Myeloma
|
Phase 3
|
9/23/2025 - evaluation
Bristol Myers Squibb announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an inve…
Full Summary
|
ELAN Elanco Animal Health |
$20.16
+2.8% |
+9.7%
 |
Zenrelia
Treatment for canine allergic itch and inflammation
|
|
9/23/2025 - Provided Update
Elanco Animal Health nnounced important updates to the U.S. Zenrelia label, following the Food and …
Full Summary
|
MCRB Seres Therapeutics |
$19.24
+2.9% |
+1.6%
 |
SER-155
Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
|
Phase 2
|
9/23/2025 - Feedback
Seres Therapeutics, announced receipt of additional constructive feedback from the U.S. Food and Dr…
Full Summary
|
ATAI atai Life Sciences |
$5.29
-2.9% |
+15.5%
 |
BPL-003
In Patients With Treatment Resistant Depression
|
|
9/23/2025 - Positive Data
atai Life Sciences announced positive data from a proof-of-concept study investigating a two-dose in…
Full Summary
|
SRRK Scholar Rock |
$37.24
-2.9% |
+14.1%
 |
Apitegromab
Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
|
|
9/23/2025 - Complete Response Letter
Scholar Rock announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Respo…
Full Summary
|
MRNA Moderna |
$25.83
+2.0% |
+7.2%
 |
COVID-19 vaccine
Covid-19
|
|
9/23/2025 - Positive Data
Moderna, Inc. announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXS…
Full Summary
|
SNSE Sensei Biotherapeutics |
$9.45
-1.0% |
+17.0%
 |
Solnerstotug
in PD-(L)1 Resistant Tumors
|
|
9/23/2025 - Provided Update
Sensei Biotherapeutics, Inc. announced that it will host a virtual key opinion leader (KOL) event on…
Full Summary
|
